Integrated Metagenomic and Metabolomic Core

综合宏基因组和代谢组核心

• 批准号: 10685510
• 负责人: SHIRISH S BARVE
• 金额: $ 36.58万
• 依托单位: VANDERBILT UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-10 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10685510
• 关键词: Affect; Aging; Alcohol consumption; Alcohols; Bile Acids; Bioinformatics; Biological Specimen Banks; Boston; Cardiovascular Diseases; Cessation of life; Clinical; Cohort Studies; Collaborations; Communities; Complement; Computational algorithm; Data; Data Analyses; Development; Ensure; Equipment and supply inventories; Evaluation; Fostering; Generations; Genes; Goals; HIV; HIV Infections; HIV/AIDS; Heavy Drinking; Human Resources; Infrastructure; Institution; Letters; Logistics; Longitudinal Studies; Longitudinal, observational study; Mass Fragmentography; Medicine; Metagenomics; Methods; Molecular; Monitor; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism; Nomenclature; Outcome; Output; Participant; Persons; Plasma; Preparation; Probiotics; Procedures; Publishing; Quality Control; RNA; Recording of previous events; Research Design; Research Personnel; Research Project Grants; Resources; Role; Russia; Sampling; Sampling Studies; Serum; Shipping; Shotguns; Site; Specimen; Standardization; Taxon; Techniques; Therapeutic; Uganda; Universities; Veterans; Volatile Fatty Acids; Work; alcohol research; biobank; clinical care; cohort; college; comorbidity; data integration; data management; data mining; data repository; data sharing; data standards; dysbiosis; efficacy evaluation; gut bacteria; gut dysbiosis; gut microbiota; host microbiota; improved; innovation; metabolome; metabolomics; metagenomic sequencing; microbial; microbiome; microbiome research; microbiota; probiotic supplementation; programs; rRNA Genes; randomized, clinical trials; sample collection; trimethyloxamine; whole genome

The Integrated Metagenomics and Metabolomics Core (IMMC) will provide a platform that interconnects Projects 1 and 2. Specifically, IMMC will provide high-quality, metagenomics and targeted metabolomics data, to be integrated with the probiotics randomized clinical trial and clinical cohort outcomes for Projects 1 and 2, respectively. The IMMC has already acquired relevant metagenomics and metabolomics data (see Preliminary data sections E1.2 and F.1.A.2) that supports the experimental rationale and study design for Projects 1 and 2. To ensure optimal scientific output from the study samples, the IMMC has implemented standardized procedures for collection of samples from Projects 1 and 2 study sites, and established logistics to coordinate shipment of samples for analysis, manage inventory, and enable tracking of chain of custody. For Project 1, IMMC - sub-core 1 will conduct state of the art metagenomics analysis of fecal samples collected from study participants receiving probiotics supplementation, to profile the changes in the gut microbial communities. The culture- independent molecular methods will consist of 16S rRNA gene and whole genome shotgun (WGS) metagenomic sequencing that provide the most comprehensive microbiota profiling. Rigorous sequence data analysis will utilize a set of advanced computational algorithms, according to taxon- based or function-based data matrices. IMMC- sub-core 2 will conduct targeted metabolomics analysis of plasma/serum (Projects 1 and 2) to monitor host and gut-microbiota metabolomes. The IMMC will collaborate with Projects to develop meaningful study designs, implement effective sample collection and storage strategies, generate high-quality metagenomics and targeted metabolomics data, computationally summarize these data and support interpretation of the results. It will implement high-quality techniques, along with quality control standards, that produce meaningful results in a timely fashion. The IMMC will also standardize data generation methods across studies to enable integration across Projects and uncover robust discoveries. To accomplish these goals the IMMC has established the following aims: 1. Employ metagenomic approaches to generate and analytically summarize project microbiome data. 2. Perform targeted metabolomics analyses to profile plasma/serum metabolites. 3. Manage specimen and data biorepository and facilitate transfer between research Projects.

综合元基因组和代谢组学核心(IMMC)将提供一个互联互通的平台 项目1和2。具体地说，IMMC将提供高质量的元基因组学和靶向代谢组学数据， 与益生菌随机临床试验和项目1和2的临床队列结果相结合， 分别进行了分析。IMMC已经获得了相关的元基因组和代谢组学数据(见初步数据 数据部分e1.2和F.1.A.2)，支持项目1和2的实验原理和研究设计。 为了确保研究样本的最佳科学产出，IMMC实施了标准化 从项目1和项目2的研究地点收集样本的程序，并建立后勤协调 运送样品以供分析、管理库存，并能够跟踪保管链。 对于项目1，IMMC-亚核1将对粪便样本进行最先进的元基因组分析 从接受益生菌补充剂的研究参与者那里收集，以描述肠道的变化 微生物群落。与培养无关的分子方法将由16S rRNA基因和全基因组组成 基因组鸟枪(WGS)元基因组测序，提供最全面的微生物区系图谱。 严格的序列数据分析将利用一套先进的计算算法，根据分类- 基于或基于函数的数据矩阵。IMMC-Sub-core 2将进行靶向代谢组学分析 监测宿主和肠道微生物区系代谢的血浆/血清(项目1和2)。 IMMC将与项目合作，开发有意义的研究设计，实施有效的样本 收集和存储策略，生成高质量的元基因组学和靶向代谢组学数据， 通过计算汇总这些数据，并支持对结果的解释。它将实施高质量 技术，以及质量控制标准，及时产生有意义的结果。IMMC 还将标准化跨研究的数据生成方法，以实现跨项目和 发现强大的发现。 为实现这些目标，IMMC确立了以下目标： 1.采用元基因组学方法生成并分析总结项目微生物组数据。 2.进行目标代谢组学分析，以分析血浆/血清代谢物。 3.管理标本和数据生物库，促进研究项目之间的转移。